Fierce Pharma

MARCH 5, 2024

A trial of Novo Nordisk's Ozempic on diabetes and kidney disease patients found that it reduced the risk of disease progression and death by 24%.

Patients 293

Patients 293

Fierce Pharma

NOVEMBER 13, 2024

Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years fkansteiner Wed, 11/13/2024 - 14:37

Patients 284

Patients 284

Fierce Pharma

APRIL 6, 2023

Pfizer escapes proposed class action lawsuit over patient copay assistance esagonowsky Thu, 04/06/2023 - 11:03

Patients 266

Patients 266

Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 243

Biopharma Patients 243

Fierce Pharma

SEPTEMBER 26, 2023

As if the talc product liability lawsuits weren’t enough headache for Johnson & Johnson, the New Jersey pharma is now facing another lawsuit from patients, this time about a recent data breach. |

Patients 262

Patients Pharma 262

Fierce Pharma

MAY 9, 2024

While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.

Leads 250

Leads Patients FDA Pharmaceutical 250

Fierce Pharma

APRIL 27, 2023

Quitting Lilly's obesity drug tirzepatide may be difficult for many patients, exec says kdunleavy Thu, 04/27/2023 - 15:08

Patients 271

Patients 271

Fierce Pharma

APRIL 9, 2024

Medication adherence is a large and growing challenge for pharma companies, healthcare providers and the patients they serve. Research shows that 20% of patients have failed to fill a script in the past, and one-third aren’t confident managing their illness. Engaging patients from the moment a drug is prescribed can help.

Prescription 227

Prescription Patients Healthcare Provider Pharma 227

Fierce Pharma

OCTOBER 25, 2024

Johnson & Johnson tested Tremfya in patients with plaque psoriasis involvement in "sensitive or highly visible areas," while Lilly weighed Ebglyss in atopic dermatitis patients who've previously tried Dupixent.

Patients 234

Patients Competition Marketing 234

Fierce Pharma

SEPTEMBER 1, 2024

With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). |

Patients 250

Patients 250

Fierce Pharma

JUNE 7, 2023

The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. | The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K.

Patients 253

Patients Government 253

Fierce Pharma

SEPTEMBER 11, 2023

After 10 years of stagnation, a new FDA approval could help more cancer patients become eligible for stem cell transplants. |

FDA 241

FDA Patients 241

Fierce Pharma

NOVEMBER 13, 2023

Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss. Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss.

Patients 265

Patients 265

Fierce Pharma

SEPTEMBER 5, 2024

AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case. AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case.

Insurance 337

Insurance Patients 337

Fierce Pharma

SEPTEMBER 5, 2023

As the Federal Trade Commission (FTC) scrutinizes Pfizer’s $43 billion Seagen buyout, the antibody-drug conjugate (ADC) specialist has notched a phase 3 win that could broaden its cervical cancer a | The drug boosted overall survival, progression-free survival and objective response rates in patients with recurrent or metastatic cervical cancer who (..)

Patients 250

Patients 250

Fierce Pharma

JANUARY 24, 2024

Today, gaining consistent access to life-saving medications can be a significant hurdle that many patients must learn to navigate. Specialty therapy patients require accessible prescription management solutions that can simplify communication, improve access, and increase adherence.

Patients 182

Patients Prescription Management Medical 182

Fierce Pharma

MARCH 17, 2023

Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years aliu Fri, 03/17/2023 - 10:22

Patients 243

Patients 243

Fierce Pharma

OCTOBER 10, 2024

Now, with new data indicating the drug could prolong patients’ lives, the company is targeting an even wider label. In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class.

Patients 216

Patients FDA 216

Fierce Pharma

JUNE 18, 2024

Authors: Arlene Pineda, Senior Director, Patient Support Services, IQVIA Kristina Jones, Principal, Patient Services Technology & Analytics, IQVIA | In a curious twist, patient support programs — often designed to alleviate the burden on patients — sometimes create unintended challenges.

Patients 163

Patients 163

Fierce Pharma

JULY 6, 2023

GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.

Patients 246

Patients 246

Fierce Pharma

AUGUST 24, 2023

mg dose bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction. Just a few short weeks after Wegovy posted a major cardio outcomes win, Novo Nordisk has chalked up another heart-related victory for its semaglutide star. |

Patients 242

Patients Medicine 242

Fierce Pharma

APRIL 14, 2023

AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin aliu Fri, 04/14/2023 - 22:19

Patients 226

Patients 226

Fierce Pharma

FEBRUARY 20, 2024

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control.

Patients 194

Patients Medical 194

Fierce Pharma

JULY 15, 2024

million gene therapy Casgevy for sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), patients must first undergo chemotherapy | Vertex has filed a lawsuit in federal court in Washington, D.C. To receive Vertex and CRISPR Therapeutics’ $2.2 against the U.S.

Patients 189

Patients 189

Fierce Pharma

DECEMBER 5, 2023

Further, the group detailed the impact of the crisis on both adult and child cancer patients. . | In its letter to congressional leaders, the American Cancer Society Cancer Action Network (ACS CAN) outlined the root causes of drug shortages and offered potential solutions.

Patients 217

Patients Networking 217

Fierce Pharma

MAY 24, 2024

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0

Patients 320

Patients 320

Fierce Pharma

AUGUST 27, 2024

Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other issues such as high prices and off-label co | Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy.

Patients 318

Patients 318

Fierce Pharma

FEBRUARY 27, 2024

Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. A seismic shift has occurred in the healthcare landscape.

Biopharma 181

Biopharma Patients Healthcare Healthcare 181

Fierce Pharma

NOVEMBER 19, 2024

KnippeRx Transforms Patient Assistance Programs through Technology and Patient-Focused Solutions. jpiatt Tue, 11/19/2024 - 10:05

Patients 130

Patients 130

Fierce Pharma

OCTOBER 3, 2024

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients 130

Patients Biopharma Management Pharma 130

Fierce Pharma

MAY 31, 2024

When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal. When companies introduce an injectable version of an intravenously infused drug, better convenience with comparable efficacy is typically the goal.

Patients 276

Patients 276

Fierce Pharma

JANUARY 4, 2024

Article by Richard Pops, CEO of Alkermes | Alkermes, a pioneer in neuroscience therapeutics, is building on its foundation as it emerges as a pure neuroscience company.

Leads 207

Leads Patients 207